【摘要】：目的探討雙黃升白顆粒預(yù)防性治療慢性丙型病毒性肝炎干擾素抗病毒治療所致白細(xì)胞計(jì)數(shù)減少的臨床療效。方法選取2011年6月—2013年6月河南省中醫(yī)院收治的慢性丙型病毒性肝炎患者62例,采用隨機(jī)數(shù)字表法分為治療組32例,對(duì)照組30例,分別于干擾素治療開(kāi)始同時(shí)服用雙黃升白顆粒(15 g/次,3次/d)和利血生(20mg/次,3次/d),然后檢測(cè)每組患者治療前,治療后2、4、8周外周血白細(xì)胞計(jì)數(shù)、中性粒細(xì)胞計(jì)數(shù)及骨髓抑制情況。結(jié)果兩組治療前后白細(xì)胞計(jì)數(shù)和中性粒細(xì)胞計(jì)數(shù)比較,差異均有統(tǒng)計(jì)學(xué)意義(P0.05);治療方法與治療時(shí)間存在交互作用(P0.05);組間比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05);時(shí)間間比較,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。對(duì)照組22例(73.3%)患者發(fā)生骨髓抑制,其中輕度14例、中度6例、重度2例;治療組12例(37.5%)患者發(fā)生骨髓抑制,其中輕度9例、中度2例、重度1例。對(duì)照組骨髓抑制發(fā)生率高于治療組(χ2=10.980,P=0.011)。結(jié)論雙黃升白顆粒預(yù)防性用藥對(duì)于治療干擾素所致白細(xì)胞計(jì)數(shù)減少較利血生效果好,同時(shí)所致骨髓抑制發(fā)生率更低,雙黃升白顆粒是一種安全有效的預(yù)防干擾素所致白細(xì)胞計(jì)數(shù)減少的有效藥物。
[Abstract]:Objective to investigate the clinical effect of Shuanghuangshengbai granule (Shuanghuangshengbai granule) on leukopenia induced by anti-viral therapy of interferon in chronic hepatitis C. Methods from June 2011 to June 2013, 62 patients with chronic hepatitis C were randomly divided into treatment group (n = 32) and control group (n = 30). Shuanghuangshengbai granules (15 g / time, 3 times / d) and 20mg/ (3 times / d),) were taken simultaneously at the beginning of interferon therapy. The peripheral blood leukocyte count, neutrophil count and bone marrow suppression were measured before and 2 weeks after treatment in each group. Results there were significant differences in leukocyte count and neutrophil count between the two groups before and after treatment (P0.05); there was interaction between the treatment methods and the treatment time (P0.05); the difference between the two groups was statistically significant (P0.05); there was a significant difference between the two groups (P0.05); The difference was statistically significant (P0.05). Bone marrow suppression occurred in 22 patients (73.3%) in the control group, including 14 mild cases, 6 moderate cases and 2 severe cases, while in the treatment group 12 cases (37.5%) developed bone marrow suppression, including 9 mild cases, 2 moderate cases and 1 severe case. The incidence of bone marrow suppression in the control group was higher than that in the treatment group (蠂 ~ 2 = 10.980). Conclusion Shuanghuangshenbai granule has a better effect on the reduction of leukocyte count induced by interferon than that on hematogenesis, and the incidence of bone marrow suppression is lower. Shuanghuangshengbai granule is a safe and effective drug to prevent interferon-induced leukopenia.
【作者單位】： 河南省中醫(yī)院;上海中醫(yī)藥大學(xué)附屬龍華醫(yī)院;鄭州市中醫(yī)院;
【分類號(hào)】：R512.63

【相似文獻(xiàn)】

相關(guān)期刊論文 前9條

1 沈云輝,陳長(zhǎng)勛,徐振曄;雙黃升白顆粒劑對(duì)小鼠白細(xì)胞減少癥的影響[J];中國(guó)中藥雜志;2005年16期

2 沈云輝;陳長(zhǎng)勛;徐振曄;;雙黃升白顆粒劑對(duì)白細(xì)胞減少癥模型小鼠造血細(xì)胞作用的研究[J];中國(guó)中藥雜志;2006年09期

3 沈云輝;陳長(zhǎng)勛;徐振曄;;雙黃升白顆粒劑升高白細(xì)胞作用機(jī)制的研究[J];中成藥;2007年04期

4 顧賢;王立芳;朱凌宇;徐振曄;;雙黃升白顆粒對(duì)化療所致骨髓抑制荷瘤小鼠細(xì)胞增殖的調(diào)控[J];江西中醫(yī)學(xué)院學(xué)報(bào);2011年04期

5 王中奇;鄧海濱;吳繼;趙曉珍;殷紅梅;徐振曄;;雙黃升白顆粒治療肺癌化療后骨髓抑制的臨床研究[J];上海中醫(yī)藥雜志;2013年06期

6 王立芳;徐振曄;金長(zhǎng)娟;沙慧芳;王中奇;周衛(wèi)東;張銘;吳繼;白冰;;雙黃升白顆粒對(duì)化療所致骨髓抑制Lewis肺癌荷瘤小鼠細(xì)胞周期的雙重調(diào)控作用及其機(jī)制[J];中西醫(yī)結(jié)合學(xué)報(bào);2009年05期

7 王爽;徐振曄;王立芳;;雙黃升白顆粒對(duì)A549肺癌荷瘤裸鼠化療期間細(xì)胞周期調(diào)控的研究[J];遼寧中醫(yī)雜志;2012年09期

8 王立芳;徐振曄;金長(zhǎng)娟;沙慧芳;王中奇;鄧海濱;;雙黃升白顆粒對(duì)Lewis肺癌荷瘤鼠細(xì)胞周期雙重調(diào)控的研究[J];上海中醫(yī)藥雜志;2009年02期

9 顧賢;徐振曄;王立芳;朱凌宇;;雙黃升白顆粒雙向調(diào)控細(xì)胞周期CyclinD-CDK4/6信號(hào)途徑的進(jìn)一步研究[J];遼寧中醫(yī)藥大學(xué)學(xué)報(bào);2011年12期

相關(guān)會(huì)議論文 前3條

1 沈云輝;陳長(zhǎng)勛;;雙黃升白顆粒劑升高白細(xì)胞作用機(jī)制的研究[A];中華中醫(yī)藥學(xué)會(huì)中藥實(shí)驗(yàn)藥理分會(huì)第六屆學(xué)術(shù)會(huì)議論文匯編[C];2006年

2 張銘;項(xiàng)怡;王立芳;徐振曄;;雙黃升白顆粒防治腫瘤化療骨髓抑制的臨床觀察[A];2012·中國(guó)醫(yī)師協(xié)會(huì)中西醫(yī)結(jié)合醫(yī)師大會(huì)第三次會(huì)議論文集[C];2012年

3 徐振曄;王立芳;;雙黃升白顆粒對(duì)荷瘤鼠化療后骨髓抑制期細(xì)胞周期的雙重調(diào)控研究[A];第十屆全國(guó)中西醫(yī)結(jié)合腫瘤學(xué)術(shù)大會(huì)論文匯編[C];2006年

，

本文編號(hào)：2262071